Enzymatic Protease Inhibition Strategies

Proteases are pivotal enzymes that catalyse the hydrolysis of peptide bonds, governing processes as diverse as digestion, blood coagulation, immune response and cell signalling. Inhibiting protease activity has thus emerged as a major therapeutic and investigative strategy, with approaches spanning reversible active‐site blockers, covalent ‘suicide’ substrates, allosteric modulators and macromolecular binders such as antibodies or protein decoys. Structure-guided design has enabled the tailoring of small molecules to exploit enzyme specificity pockets, while peptidomimetic chemistry has furnished compounds that mimic transition-state geometry to achieve high potency. Advances in fragment screening and computational docking have accelerated the discovery of novel scaffolds, some of which engage non-catalytic surfaces to induce conformational changes that abrogate activity. The global significance of these efforts is underscored by applications ranging from antiviral agents targeting viral proteases to anti-inflammatory drugs directed at neutrophil elastase. Contemporary research increasingly integrates dynamic structural information and high-throughput kinetics to refine selectivity, improve pharmacokinetics and minimise off-target effects, thereby broadening the practical scope of protease inhibition in medicine and biotechnology.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Enzymatic Protease Inhibition Strategies publication trend

The graph below shows the total number of articles in enzymatic protease inhibition strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Competitive inhibitor: A molecule that binds directly to an enzyme’s active site and competes with substrate binding.

Covalent inhibitor: An inhibitor that forms a permanent or reversible covalent bond with a catalytic residue, often yielding prolonged enzyme inactivation.

Allosteric site: A regulatory region distinct from the enzyme’s active site, where ligand binding alters enzyme conformation and activity.

Peptide boronic acid: A class of protease inhibitors featuring a boronic acid moiety that reversibly forms a tetrahedral adduct with the catalytic serine.

Slow-binding kinetics: A kinetic mechanism in which inhibitor association or conformational adjustment occurs in multiple steps, resulting in time-dependent strengthening of the enzyme–inhibitor complex.

References

1. Small molecule inhibitors of mesotrypsin from a structure-based docking screen. PLOS ONE (2017).
2. Inhibition of the serine proteases leukocyte elastase, pancreatic elastase, cathepsin G, and chymotrypsin by peptide boronic acids.. Journal of Biological Chemistry (1984).